Immune Profiles Evolution Under Immunotherapy for Melanoma

The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association of these immune profiles with relapse- or progression-free survival.

Trial Details

NCT ID
NCT04576429
Phase
NA
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • venous puncture
  • tumoral biopsy
Locations (sample)
  • Boulogne-Billancourt, France|48.83545,2.24128

Key Eligibility Criteria

  • Patient aged ≥ 18 years;
  • Totally resected stage III or IV melanoma totally resected, treated with a immune therapy (pembrolizumab or nivolumab ou other immune checkpoint in…
  • Unresectable stage IIIC/D or IV metastatic melanoma, treated with immune therapy (pembrolizumab or nivolumab or immune checkpoint inhibitors) which…
  • Patient has been informed about the study and signed the consent;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →